ArticleJournal of medicinal chemistry2021
Oxidative Metabolism as a Modulator of Kratom's Biological Actions.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Reported associations between kratom and seizures: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Simultaneous quantification of seventeen kratom alkaloids and metabolites in human plasma and its application to clinical pharmacokinetic sample analysis.Pharmaceutical biology · 2026Article
- Atypical respiration patterns of kratom alkaloids.The Journal of pharmacology and experimental therapeutics · 2026Article
- Investigating Opioid Receptor Activity through Biocatalytic Halogenation and Oxidation of Mitragynine.ACS chemical biology · 2026Article
- Indole Alkaloids as Biased Opioid Receptor Modulators.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mixtures Biotransformation: Multilayer Molecular Networking of Kratom Liver Metabolites.Journal of natural products · 2026Article
- 7-OH and kratom vaping products: an emerging public health threat.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Semi-synthesis in the exploration of opioid-targeting natural products.Natural product reports · 2025Review
- Synthesis and Pharmacology of a Morphinan-Derived Dual Mu-Kappa Opioid Receptor Agonist Analgesic.ACS chemical neuroscience · 2025Article
- Integration of computational models to predict botanical phytochemical constituent clearance routes by the Extended Clearance Classification System (ECCS).Toxicology and applied pharmacology · 2025Article
- De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing.Drug and alcohol dependence · 2025Article
- Quantification of 11 kratom alkaloids including mitragynine and its main metabolites in human plasma using LC-MS/MS.Analytical and bioanalytical chemistry · 2025Article
- The acute adverse health effects of kratom: an evaluation of case reports.Frontiers in pharmacology · 2025Review
- Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine.Journal of medicinal chemistry · 2024Article
- Signaling Modulation Mediated by Ligand Water Interactions with the Sodium Site at μOR.ACS central science · 2024Article
- Multiple-Dose Pharmacokinetics and Safety of Mitragynine, the Major Alkaloid of Kratom, in Rats.ACS pharmacology & translational science · 2024Article
- Article
- An In Vitro Examination of Whether Kratom Extracts Enhance the Cytotoxicity of Low-Dose Doxorubicin against A549 Human Lung Cancer Cells.Molecules (Basel, Switzerland) · 2024Article
- Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers.ACS pharmacology & translational science · 2024Article
- Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 2 countries.
Soumen ChakrabortyCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy and Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Rajendra UpretyDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Samuel T SlocumDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Takeshi IrieDepartment of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Valerie Le RouzicDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Xiaohai LiDepartment of Molecular Therapeutics, Scripps Research Institute, Jupiter, Florida 33458, United States.
Lisa L WilsonDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0001-7770-8726
Brittany ScoullerCentre for Biodiscovery, School of Biological Science, Victoria University of Wellington, Wellington 6012, New Zealand.
Amy F AlderCentre for Biodiscovery, School of Biological Science, Victoria University of Wellington, Wellington 6012, New Zealand.
Andrew C KruegelDepartment of Chemistry, Columbia University, New York 10027, United States.
Michael AnsonoffDepartment of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey 08854-8021, United States.
Andras VaradiDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.ORCID 0000-0001-5591-377X
Shainnel O EansDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, United States.
Amanda HunkeleDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Abdullah AllaoaDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Sanjay KalraDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Jin XuDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Ying Xian PanDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
John PintarDepartment of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey 08854-8021, United States.
Bronwyn M KivellCentre for Biodiscovery, School of Biological Science, Victoria University of Wellington, Wellington 6012, New Zealand.
Gavril W PasternakDepartment of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York 10065, United States.
Michael D CameronDepartment of Molecular Therapeutics, Scripps Research Institute, Jupiter, Florida 33458, United States.ORCID 0000-0003-3154-4775
Jay P McLaughlinDepartment of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, United States.ORCID 0000-0001-9851-9342
Dalibor SamesDepartment of Chemistry, Columbia University, New York 10027, United States.
Susruta MajumdarCenter for Clinical Pharmacology, University of Health Sciences & Pharmacy and Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0002-2931-3823
Memorial Sloan Kettering Cancer Center · USUniversity of Florida · USVictoria University of Wellington · NZColumbia University · USRutgers, The State University of New Jersey · USScripps Research Institute · USUniversity of Health Sciences and Pharmacy · USUniversity of North Carolina at Chapel Hill · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MChemistry and Pharmacology of Iboga AlkaloidsR01DA050613 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DALIBOR SAMES · 2020 to 2026
$4.1MChemistry and Biology of Mitragynine AlkaloidsR01DA046487 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2018 to 2022
$3.0MPharmacological Probes based on mitragynine pseudoindoxylR33DA045884 · NIDA · ST. LOUIS COLLEGE OF PHARMACY · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2020 to 2021
$792kAnalgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)R21DA034106 · NIDA · SLOAN-KETTERING INST CAN RESEARCH · PI MAJUMDAR, SUSRUTA · 2012 to 2013
$443kPharmacological Probes based on mitragynine pseudoindoxylR21DA045884 · NIDA · ST. LOUIS COLLEGE OF PHARMACY · PI MAJUMDAR, SUSRUTA, SAMES, DALIBOR · 2018 to 2019
$437kOpioidergic alkaloids from Mitragynia Speciosa (kratom) as novel treatment for alcohol use disorderR21AA026949 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M. · 2018 to 2019
$421kNCI NIH HHS P30 CA008748NIAAA NIH HHS R21 AA026949NIDA NIH HHS R01 DA046487NIDA NIH HHS R01 DA050613NIDA NIH HHS R21 DA034106NIDA NIH HHS R21 DA045884NIDA NIH HHS R33 DA045884
Abstract
The leaves of
Indexed as
AnimalsMiceMice, Inbred C57BLMice, KnockoutOxidation-ReductionReceptors, Opioid, muSecologanin Tryptamine AlkaloidsmitragynineReceptors, Opioid, muSecologanin Tryptamine Alkaloids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.